Search results
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Digital Journal· 4 days ago(NASDAQ:MRNA) today announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the ...
Chu Teh-Chun's Abstract Landscapes Dazzle in a Rare Retrospective
Artnet News· 21 hours agoThe name of Chu Teh-Chun (1920–2014) should be no stranger to art market watchers. The late...
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and...
FOX 23 News Albany· 2 days agoOncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American ...
AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting
Quincy Herald-Whig· 2 days ago...AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that data from its C-CAR031 study has been published in an abstract available on the 2024 American...
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 3 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2...
FOX 59 Indianapolis· 2 days ago~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatmentMedian tumor shrinkage (maximum volume change) of ~39% after 6 monthsClinical ...
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
KTLA-TV Los Angeles· 2 days agoShanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical ...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating...
FOX 23 News Albany· 2 days agoBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing...
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
ThePress.net· 3 days agoThe ASCO Annual Meeting is being held online and in person in Chicago, Illinois from May 31 to June 4, 2024. The EHA2024 Congress is being held online and in person in Madrid, Spain from June 13 to June 16, 2024.
2025 Real ID Deadline Seems Likely to Stick in California
Government Technology· 2 days ago(TNS) — Pushed out of mind by a handful of deadline delays, Californians now face another drop-dead...